Takeda tightens focus on core areas with multiple deals

Japanese pharmaceutical giant Takeda is remodelling its R&D pipeline with a series of deals, refocusing and expanding its three core disease areas through partnerships, acquisitions and licensing agreements.

The company has formed more than 50 collaborations over the last 18 months with the aim of increasing its R&D capabilities, partnering with companies and institutions such as AstraZeneca, Samsung Bioepis and Stanford University to fund work towards the development of new drugs.